Article

IntraLens Vision changes name, sets its sights on presbyopia market

IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.

Chicago-IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.

“We feel our new name, ReVision Optics, perfectly suits both our corporate mission and our products. ReVision Optics will be targeting the refractive surgery market with an emphasis on the surgical correction of presbyopia via an intracorneal lens,” said J. Randy Alexander, president of ReVision Optics.

Alexander added that IntraLase Corp. has agreed to develop specialized software that will enable ReVision Optics to develop the collateral products to move forward in the marketplace. The software will enable ReVision Optics to produce two types of customized flaps that will assist eye surgeons to inject the company’s intracorneal lenses easily. The company’s lenses are undergoing clinical trial in the United States.

“While continuing to gain global market share of corneal flaps for LASIK, an integral part of our strategy is also to establish our laser as enabling technology for corneal applications which include corneal inlays, rings, and therapeutic procedures,” said Robert J. Palmisano, IntraLase president and chief executive officer.

As part of this agreement with ReVision, IntraLase will acquire full rights to the name IntraLens.

ReVision Optics will develop, manufacture, and market intracorneal lenses to correct and maintain vision. The lenses are made from a proprietary microporous hydrogel material and will be trademarked under the name PresbyLens.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.